<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://mfrdinfo.com/ems1/index.php?action=history&amp;feed=atom&amp;title=Antiarrhythmics</id>
	<title>Antiarrhythmics - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://mfrdinfo.com/ems1/index.php?action=history&amp;feed=atom&amp;title=Antiarrhythmics"/>
	<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;action=history"/>
	<updated>2026-08-16T12:21:11Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.32.0</generator>
	<entry>
		<id>http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=16035&amp;oldid=prev</id>
		<title>Mfrdmanager: /* Adenosine (ADENOCARD) / Antiarrhythmic */</title>
		<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=16035&amp;oldid=prev"/>
		<updated>2018-03-21T21:06:06Z</updated>

		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Adenosine (ADENOCARD) / Antiarrhythmic&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 21:06, 21 March 2018&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l19&quot; &gt;Line 19:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 19:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* Heart transplant patients may only require a smaller dosage and patients on Theophylline based medications may require larger dosage, contact MEDICAL CONTROL for consult.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* Heart transplant patients may only require a smaller dosage and patients on Theophylline based medications may require larger dosage, contact MEDICAL CONTROL for consult.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''DOSAGE:'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;'''DOSAGE:'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* IV &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;6 &lt;/del&gt;mg by rapid IV bolus, if no results repeat 1-2 minutes later as 12 mg rapid IV bolus. Maximum total dose &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;18 &lt;/del&gt;mg.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* IV &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;12 &lt;/ins&gt;mg by rapid IV bolus, if no results repeat 1-2 minutes later as 12 mg rapid IV bolus. Maximum total dose &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;24 &lt;/ins&gt;mg.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* Pediatrics - Refer to Handtevy System for patient specific dosage&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* Pediatrics - Refer to Handtevy System for patient specific dosage&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** Premies - 13 y/o: 0.1 mg/kg (1st dose), 0.2 mg/kg (2nd dose)&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** Premies - 13 y/o: 0.1 mg/kg (1st dose), 0.2 mg/kg (2nd dose)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Atropine Sulfate / ANTIMUSCARINICS / ANTIDOTES====&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Atropine Sulfate / ANTIMUSCARINICS / ANTIDOTES====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Mfrdmanager</name></author>
		
	</entry>
	<entry>
		<id>http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=12294&amp;oldid=prev</id>
		<title>Mfrdmanager: /* Amiodarone / Antiarrhythmic */</title>
		<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=12294&amp;oldid=prev"/>
		<updated>2018-03-15T11:30:08Z</updated>

		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Amiodarone / Antiarrhythmic&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 11:30, 15 March 2018&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l67&quot; &gt;Line 67:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 67:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;====Amiodarone / Antiarrhythmic====&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;'''DESCRIPTION:'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Class III antidysrhythmic that prolongs the cardiac action potential and repolarization phase of the cardiac cycle. It shows beta-blocker and potassium channel blocker properties thus reducing dysrhythmias. It has complex drug effects on sodium and potassium.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;'''INDICATIONS:'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Ventricular Fibrillation]], [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Pulseless V-Tach]] (4.08), [[Ventricular Tachycardia with a Palpable Pulse|V-Tach with a pulse]] (4.09).&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;'''CONTRAINDICATIONS:'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Sinus bradycardia, AV blocks.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;'''PRECAUTIONS:'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Not recommended for pregnant or nursing mothers.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Multiple drug interactions – interacts with digoxin, warfarin, phenytoin.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* When given concurrently with simvastatin (cholesterol drugs) it increases the risk for rhabdomyolysis and renal failure.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;'''DOSAGE:'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Adult&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;** VF/VT – 300 mg IVP, IO. May repeat once with 150 mg IVP, IO if dysrhythmia is not suppressed with initial dose.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;** VT with a pulse – 150 mg diluted in 50 ml (Buretrol) over 10 minutes.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;* Pediatric - Refer to Handtevy System for pediatric specific dosage.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;** VF/VT - 5 mg/kg, can repeat dose in 5 mg/kg doses to max of 15 mg/kg total dose.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Medication Guidelines|0806]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Medication Guidelines|0806]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Mfrdmanager</name></author>
		
	</entry>
	<entry>
		<id>http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=248&amp;oldid=prev</id>
		<title>Mfrdmanager at 17:19, 10 February 2018</title>
		<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=248&amp;oldid=prev"/>
		<updated>2018-02-10T17:19:13Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 17:19, 10 February 2018&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;__NOTOC__&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Section 8 - MEDICATION GUIDELINES==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Section 8 - MEDICATION GUIDELINES==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===8.06 ANTIARRHYTHMICS===&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===8.06 ANTIARRHYTHMICS===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Mfrdmanager</name></author>
		
	</entry>
	<entry>
		<id>http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=245&amp;oldid=prev</id>
		<title>Mfrdmanager: Protected &quot;Antiarrhythmics&quot; ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))</title>
		<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=245&amp;oldid=prev"/>
		<updated>2018-02-10T17:18:02Z</updated>

		<summary type="html">&lt;p&gt;Protected &amp;quot;&lt;a href=&quot;/ems1/index.php?title=Antiarrhythmics&quot; title=&quot;Antiarrhythmics&quot;&gt;Antiarrhythmics&lt;/a&gt;&amp;quot; ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 17:18, 10 February 2018&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-notice&quot; lang=&quot;en&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(No difference)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</summary>
		<author><name>Mfrdmanager</name></author>
		
	</entry>
	<entry>
		<id>http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=244&amp;oldid=prev</id>
		<title>Mfrdmanager: Created page with &quot;==Section 8 - MEDICATION GUIDELINES== ===8.06 ANTIARRHYTHMICS===  ====Adenosine (ADENOCARD) / Antiarrhythmic==== '''DESCRIPTION/ACTION:''' * It is a natural occurring agent th...&quot;</title>
		<link rel="alternate" type="text/html" href="http://mfrdinfo.com/ems1/index.php?title=Antiarrhythmics&amp;diff=244&amp;oldid=prev"/>
		<updated>2018-02-10T17:17:54Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Section 8 - MEDICATION GUIDELINES== ===8.06 ANTIARRHYTHMICS===  ====Adenosine (ADENOCARD) / Antiarrhythmic==== &amp;#039;&amp;#039;&amp;#039;DESCRIPTION/ACTION:&amp;#039;&amp;#039;&amp;#039; * It is a natural occurring agent th...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Section 8 - MEDICATION GUIDELINES==&lt;br /&gt;
===8.06 ANTIARRHYTHMICS===&lt;br /&gt;
&lt;br /&gt;
====Adenosine (ADENOCARD) / Antiarrhythmic====&lt;br /&gt;
'''DESCRIPTION/ACTION:'''&lt;br /&gt;
* It is a natural occurring agent that can &amp;quot;chemically cardiovert&amp;quot; Paroxysmal Supraventricular Tachycardia (PSVT) to a normal sinus rhythm.&lt;br /&gt;
* It has a half-life of 5 seconds and does not cause hypotension like Verapamil.&lt;br /&gt;
* Restores normal sinus rhythm by interrupting re-entrant pathways in the AV node.&lt;br /&gt;
* Slows conduction time through the AV node.&lt;br /&gt;
* Produces coronary artery vasodialation.&lt;br /&gt;
'''INDICATIONS:'''&lt;br /&gt;
* [[Supraventricular Tachycardia|Narrow complex (PSVT)]] refractory to vagal maneuvers.&lt;br /&gt;
'''CONTRAINDICATIONS:'''&lt;br /&gt;
* 2nd and 3rd Degree Heart Block, Sick Sinus Syndrome, or known hypersensitivity to the medication.&lt;br /&gt;
'''PRECAUTIONS:'''&lt;br /&gt;
* It may cause transient arrhythmias.&lt;br /&gt;
* It may cause bronchospasm in asthma patients.&lt;br /&gt;
* Heart transplant patients may only require a smaller dosage and patients on Theophylline based medications may require larger dosage, contact MEDICAL CONTROL for consult.&lt;br /&gt;
'''DOSAGE:'''&lt;br /&gt;
* IV 6 mg by rapid IV bolus, if no results repeat 1-2 minutes later as 12 mg rapid IV bolus. Maximum total dose 18 mg.&lt;br /&gt;
* Pediatrics - Refer to Handtevy System for patient specific dosage&lt;br /&gt;
** Premies - 13 y/o: 0.1 mg/kg (1st dose), 0.2 mg/kg (2nd dose)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
====Atropine Sulfate / ANTIMUSCARINICS / ANTIDOTES====&lt;br /&gt;
'''DESCRIPTION / ACTION:'''&lt;br /&gt;
* It blocks the parasympathetic nervous system and it’s inhibiting effects on heart rate.&lt;br /&gt;
* It does not increase the strength of cardiac contraction.&lt;br /&gt;
'''INDICATIONS:'''&lt;br /&gt;
* [[Supraventricular Bradycardia and AV Blocks|Symptomatic Bradycardia]], [[Asystole]] if clinically indicated (vagally induced), and [[Drug Overdose Poisoning|Organophosphate Poisoning]].&lt;br /&gt;
'''CONTRAINDICATIONS:'''&lt;br /&gt;
* None in the emergency setting.&lt;br /&gt;
'''PRECAUTIONS:'''&lt;br /&gt;
* Give no more than 3.0 mg for cardiac-related problems. May cause a decrease in ventricular rate in the presence of 2nd Degree Mobitz II and 3rd Degree Heart Block.&lt;br /&gt;
'''DOSAGE''':&lt;br /&gt;
* 0.5 mg - 1.0 mg IVP AND refer to appropriate PRACTICE PARAMETER for specific dosage.&lt;br /&gt;
* Refer to Handtevy System for pediatric specific dosage.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
====Lidocaine 2% (XYLOCAINE) / Antidysrrhythmic====&lt;br /&gt;
'''DESCRIPTION:'''&lt;br /&gt;
* Lidocaine is an agent that increases the fibrillation threshold thereby reducing the development of ectopy and Ventricular Fibrillation.&lt;br /&gt;
'''INDICATIONS:'''&lt;br /&gt;
* More than 6 [[Premature Ventricular Contractions (PVC)|unifocal PVCs]] / minute, [[Premature Ventricular Contractions (PVC)|multifocal PVCs]], R on T phenomenon, couplets, runs of PVCs, [[Ventricular Tachycardia with a Palpable Pulse|Ventricular Tachycardia]], and in [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|V-Fib/Pulseless Ventricular Tachycardia]].&lt;br /&gt;
* May be used to enhance RSI in head injuries and may be useful in seizures caused by head injuries.&lt;br /&gt;
'''CONTRAINDICATIONS:'''&lt;br /&gt;
* 2nd degree Mobitz II and 3rd Degree Heart Blocks and bradycardias.&lt;br /&gt;
'''PRECAUTIONS:'''&lt;br /&gt;
* Side effects include: lowering LOC, confusion, irritability, muscle spasm, seizures, coma and possibly death.&lt;br /&gt;
'''DOSAGE:'''&lt;br /&gt;
* 0.5 - 1.5 mg / kg AND refer to appropriate PRACTICE PARAMETER for specific dosages.&lt;br /&gt;
* Refer to Handtevy System for pediatric specific dosage.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
====Diltiazem (CARDIZEM) / Calcium Channel Blocker====&lt;br /&gt;
'''DESCRIPTION:'''&lt;br /&gt;
* Slows conduction through the SA / AV node, Causes vasodilation.&lt;br /&gt;
'''INDICATIONS:'''&lt;br /&gt;
* [[Atrial Fibrillation Atrial Flutter|ATRIAL FIBRILLATION, ATRIAL FLUTTER]]. PRACTICE PARAMETER (4.03)&lt;br /&gt;
'''CONTRAINDICATIONS:'''&lt;br /&gt;
* HYPOTENSION, wide complex tachycardia, conduction system disturbances.&lt;br /&gt;
'''PRECAUTIONS:'''&lt;br /&gt;
* CHF, Hypotension, renal disease.&lt;br /&gt;
'''DOSAGE:'''&lt;br /&gt;
* 0.25 mg/kg IV bolus over 2 minutes AND refer to appropriate PRACTICE PARAMETERS for specific dosages.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
====Amiodarone / Antiarrhythmic====&lt;br /&gt;
'''DESCRIPTION:'''&lt;br /&gt;
* Class III antidysrhythmic that prolongs the cardiac action potential and repolarization phase of the cardiac cycle. It shows beta-blocker and potassium channel blocker properties thus reducing dysrhythmias. It has complex drug effects on sodium and potassium.&lt;br /&gt;
'''INDICATIONS:'''&lt;br /&gt;
* [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Ventricular Fibrillation]], [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Pulseless V-Tach]] (4.08), [[Ventricular Tachycardia with a Palpable Pulse|V-Tach with a pulse]] (4.09).&lt;br /&gt;
'''CONTRAINDICATIONS:'''&lt;br /&gt;
* Sinus bradycardia, AV blocks.&lt;br /&gt;
'''PRECAUTIONS:'''&lt;br /&gt;
* Not recommended for pregnant or nursing mothers.&lt;br /&gt;
* Multiple drug interactions – interacts with digoxin, warfarin, phenytoin.&lt;br /&gt;
* When given concurrently with simvastatin (cholesterol drugs) it increases the risk for rhabdomyolysis and renal failure.&lt;br /&gt;
'''DOSAGE:'''&lt;br /&gt;
* Adult&lt;br /&gt;
** VF/VT – 300 mg IVP, IO. May repeat once with 150 mg IVP, IO if dysrhythmia is not suppressed with initial dose.&lt;br /&gt;
** VT with a pulse – 150 mg diluted in 50 ml (Buretrol) over 10 minutes.&lt;br /&gt;
* Pediatric - Refer to Handtevy System for pediatric specific dosage.&lt;br /&gt;
** VF/VT - 5 mg/kg, can repeat dose in 5 mg/kg doses to max of 15 mg/kg total dose.&lt;br /&gt;
&lt;br /&gt;
[[Category:Medication Guidelines|0806]]&lt;/div&gt;</summary>
		<author><name>Mfrdmanager</name></author>
		
	</entry>
</feed>